Janone selects cpc clinical research as trial manager for phase 2b study of jan101 for peripheral artery disease patients

Las vegas, july 22, 2021 /prnewswire/ -- janone inc. (nasdaq: jan), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected cpc clinical research (cpc), a full-service academic research organization (aro), as manager for its upcoming phase 2b clinical trial of lead product candidate jan101 for treating peripheral artery disease (pad). cpc will be responsible for the planning, organization, day-to-day execution, and management of the company's study, and will collaborate with janone's appointed regulatory partner avania, announced last month.
JAN Ratings Summary
JAN Quant Ranking